Abstract
To simply define the breadth and depth of knowledge that is encompassed by the discipline of toxicology is a very difficult task and is no easier today than since its early inception in ancient times. In 1799 the first formalized attestation of the term “toxicology” (/ˌtɒksɪˈkɒlədʒi/) was made and the term is actually a neoclassical compound word from Neo-Latin that derives from a combination of the forms toxico- + -logy, which in turn originates from the Ancient Greek words τοξικός toxikos, “poisonous”, and λόγος logos, “subject matter” (Merriam-Webster 2023). If the definition of “toxicology” is reviewed in the Merriam-Webster (or equivalent lexicographical reference) dictionary, it is simply defined as the “scientific study of the adverse effects of chemical substances on the living organism”. While this is true and fit for use by the public, the term “toxicology” as a broader definition, and from a medical perspective, can be defined as “a science that studies poisons and their effects, as well as the problems involved (i.e., from a clinical, industrial, or legal problem perspective)”. To a toxicologist, however, these definitions are not incorrect but are not what we, as safety scientists, envisage as our definition of the discipline that we practice as toxicologists. Regardless, we do live the toxicology maxim famously coined by Paracelsus (Theophrastus Phillipus Auroleus Bombastus von Hohenheim) as “Alle Dinge sind Gift und nichts ist ohne Gift; allein die Dosis macht, dass sein Ding kein Gift ist” which translates as “All things are poisonous and nothing is without poison; only the dose makes a thing not poisonous” (Ottoboni 1991).
References and Further Reading
21 CFR Part 58 (1978) The Food and Drug Administration’s good laboratory practice for nonclinical laboratory studies. Retrieved October 2023 from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58
21 CFR Part 11 (1997) Guidance for Industry Part 11, electronic records; Electronic signatures – scope and application. Retrieved October 2023 from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
21 CFR Part 11 (2003) Guidance for Industry Part 11, electronic records; Electronic signatures – scope and application. Retrieved October 2023 from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
Cronin MT, Bajot F, Enoch SJ, Madden JC, Roberts DW, Schwöbel J (2009) The in chemico-in silico interface: challenges for integrating experimental and computational chemistry to identify toxicity. Altern Lab Anim 37(5):513–521
Dorato MA, Engelhardt JA (2005) The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s). Regul Toxicol Pharmacol 42:265–274
FDA (2005) Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Retrieved November 2023 from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers
Gerberick F, Aleksic M, Basketter D, Casati S, Karlberg AT, Kern P, Kimber I, Lepoittevin J-P, Natsch A, Ovigne JM, Rovida C, Sakaguchi H, Schultz T (2008) Chemical reactivity measurement and the predictive identification of skin sensitisers. The report and recommendations of ECVAM Workshop 64. Altern Lab Anim 36:215–242
Hasselgren C, Ahlberg E, Akahori Y et al (2019) Genetic toxicology in silico protocol. Regul Toxicol Pharmacol 107:104403. https://doi.org/10.1016/j.yrtph.2019.104403
ICH M3(R2) (2010) Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Retrieved October 2023 from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization
ICH M7(R2) (2023) Assessment and control of DNA reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenicity risk. Retrieved October 2023 from https://www.ema.europa.eu/en/documents/scientific-guideline/ich-m7r2-guideline-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf
ICH Q3A(R2) (2006) Impurities in new drug substances – scientific guideline. Retrieved October 2023 from https://www.ema.europa.eu/en/ich-q3a-r2-impurities-new-drug-substances-scientific-guideline
ICH S4A (1999) Duration of chronic toxicity testing in animals (Rodent and nonrodent toxicity testing). Fed Regist 64(122):34259–23260
Kale VP, Bebenek I, Ghantous H, Kapeghian J, Singh BP, Thomas LJ (2022) Practical considerations in determining adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in nonclinical safety studies: challenges, perspectives and case studies. Int J Toxicol 41(2):143–162
Koshman Y, Winters BR, Ryans J, Authier S, Pugsley MK (2024) Maximum Tolerated Dose (MTD) studies in drug toxicology assessments. In: Hock FJ, Pugsley MK (eds) Drug discovery and evaluation: safety and pharmacokinetic assays, 3rd edn. Springer Nature Press, Cham
Kreiling R, Gehrke H, Broschard TH et al (2017) In chemico, in vitro and in vivo comparison of the skin sensitizing potential of eight unsaturated and one saturated lipid compounds. Regul Toxicol Pharmacol 90:262–276
Leung CM, de Haan P, Ronaldson-Bouchard K, Kim G-A, Ko J et al (2022) A guide to the organ on a chip. Nat Rev Methods Primers 2(33). https://doi.org/10.1038/s43586-022-00118-6
McGivern JV, Ebert AD (2014) Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. Adv Drug Deliv Rev 69–70:170–178
Merriam-Webster.com Dictionary, “Toxicology”. Merriam-Webster.com Dictionary. Retrieved November 2023 from https://www.merriam-webster.com/dictionary/toxicology
Miller L, Winters BR, Authier S, Ryans J, Pugsley MK (2024) Dose Range Finding (DRF) studies in drug toxicology assessments. In: Hock FJ, Pugsley MK (eds) Drug discovery and evaluation: safety and pharmacokinetic assays, 3rd edn. Springer Nature Press, Cham
OECD (2023) Test No. 442C: In: Chemico skin sensitization: assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins, OECD guidelines for the testing of chemicals, Section 4. OECD Publishing, Paris. Retrieved October 2023 from https://doi.org/10.1787/9789264229709-en
Ottoboni MA (1991) The dose makes the poison: a plain-language guide to toxicology, 2nd edn. Van Nostrand Reinhold, New York
Pointon A, Harmer AR, Dale IL et al (2015) Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 44(2):227–237
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2024 Springer Nature Switzerland AG
About this entry
Cite this entry
Pugsley, M.K., Bhardwaj, M.K., Winters, B.R. (2024). An Introduction to Safety Toxicology. In: Hock, F.J., Pugsley, M.K. (eds) Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Springer, Cham. https://doi.org/10.1007/978-3-030-73317-9_115-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-73317-9_115-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-73317-9
Online ISBN: 978-3-030-73317-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences